Boundless Bio is a biopharmaceutical company focused on developing transformative cancer treatments, specifically targeting extrachromosomal DNA (ecDNA)-driven cancers. Led by CEO Zachary Hornby, the team includes experienced oncology leaders like Neil Abdollahian, Chief Business Officer, and Chris Hassig, Chief Scientific Officer, alongside scientific and clinical advisors from top institutions like Stanford and Harvard. The company's mission is to pioneer ecDNA-directed therapies (ecDTx) for patients with hard-to-treat cancers. Guided by boldness, creativity, and collaboration, Boundless Bio is committed to delivering innovative oncology solutions, supported by investors and a dedicated board of directors, including Chairman and Co-Founder Jonathan Lim.